Climate Change Data

Brii Biosciences Limited

Climate Impact & Sustainability Data (2021, 2023)

Reporting Period: 2021

Environmental Metrics

Total Carbon Emissions:125.64 tons of carbon dioxide (Scope 2)
Scope 2 Emissions:125.64 tons of carbon dioxide
Total Energy Consumption:144,171 kWh
Water Consumption:1,350 tons
Waste Generated:9.04 tons
Carbon Intensity:1.74 tons Carbon Dioxide Equivalent/person

ESG Focus Areas

  • Governance
  • Product Responsibility
  • Patient Advocacy
  • Employees
  • Ecological Harmony

Environmental Achievements

  • Established a carbon emission management system and strived to reduce carbon emissions year by year.
  • Improved environmental management and related data tracking and collecting procedures.
  • Increased employee training and raised awareness of carbon reduction goals.
  • Further enhanced waste management and increased the percentage of waste properly classified, recycled, and disposed of.
  • Increased advocacy and awareness on waste classification and disposal process.
  • Provided waste management training to employees and contract workers.
  • Continuously monitored office energy consumption and improved office energy efficiency year by year.
  • Increased promotion of energy-saving practices and raised awareness of energy efficiency targets.
  • Designated on-site engineer to monitor and check air conditioning system and lighting daily to avoid unnecessary energy waste.
  • Kept monitoring office water consumption and gradually increased water efficiency.
  • Put up signs around the office to increase awareness of water usage.

Social Achievements

  • Expanded the number of employees by 68.7%
  • Donated nearly 3,000 doses of monoclonal neutralizing antibody therapy for emergency use in China.
  • Completed HBV patient enrollment of BRII-179(VBI-2601)/BRII-835(VIR-2218) combination Phase 2 trial.
  • Successfully established partnership with Sinopharm Group to advance stockpiling, channel distribution and regional access of amubarvimab/romlusevimab combination.
  • Implemented comprehensive procedures and various channels for reporting and monitoring corruption incidents.
  • Conducted a total of 270 hours of compliance trainings.

Governance Achievements

  • Adopted the Corporate Governance Code as set out in Appendix 14 of the Listing Rules.
  • Established four committees (Audit, Nomination, Remuneration, and Strategy) for overseeing the Company’s affairs.
  • Adopted a “Board Diversity Policy”.
  • Established Anti-Bribery and Anti-Corruption Policy.
  • Implemented Medical Interaction and Promotion Policy.
  • Established comprehensive ESG structure.

Climate Goals & Targets

Environmental Challenges

  • COVID-19 pandemic and its impact on global economy and human lives.
  • Climate change risks (physical and transition risks).
Mitigation Strategies
  • Pivoted from other research programs to develop COVID-19 treatment.
  • Developed amubarvimab/romlusevimab combination therapy, approved by China NMPA.
  • Developed extreme weather emergency response plans.
  • Kept up-to-date with climate disclosure requirements and strengthened climate disclosure.
  • Stayed up-to-date on climate-related laws and regulations.
  • Explored opportunities related to emissions trading.
  • Continued to improve supplier risk assessment and management.
  • Enhanced monitoring of international raw material price trends.

Supply Chain Management

Supplier Audits: 13 suppliers evaluated in 2021

Responsible Procurement
  • Purchase Process for non-GxP vendors.
  • Vendor Selection and Vendor Qualification for GxP vendors.
  • Comprehensive procedure for assessing prospective suppliers for quality, industry experience, labor management, and environmental and social credentials.

Climate-Related Risks & Opportunities

Physical Risks
  • Increased severity of extreme weather events
  • Long-term shifts in climate patterns
Transition Risks
  • Changing customer or community perceptions
  • Climate-related regulation and litigation
  • Increased cost of raw materials

Reporting Standards

Frameworks Used: Appendix 27 “Environmental, Social and Governance Reporting Guide” of the Listing Rules issued by the Stock Exchange, United Nations Sustainable Development Goals

Awards & Recognition

  • eMedClub Bio-innovative Drug Most Growth Annual Award in 2021
  • PharmaDJ & Clinical Trial Best IPO of the Year 2021
  • Biocentury & Bayhalix R&D Achievement of the Year 2021
  • Xueqiu Broker Listed Company with the Most Growth Potential in 2021
  • Gelonghui Greater China Best Listed Company Awards 2021 - Most Valuable IPO of the Year
  • Gelonghui Greater China Best Listed Company Awards 2021 - Most Social Responsibility Award
  • IR Magazine 2021 Best IR Practice in Greater China
  • SINA Finance Best CFO of Hong Kong and US Listed Companies in 2021
  • SINA Finance Best New Economy Listed Company Performance Award in 2021
  • IRSC Best Capital Market Communication Award in 2021
  • Zhitongcaijing Best IR of the Year 2021
  • Zhitongcaijing Best Golden Hong Kong Stocks Awards in 2021
  • China Times Industry Leader of the Year 2021 - BriiBio CEO Hong Zhi

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:68.67 tCO2e/year (Scope 2)
Scope 1 Emissions:0 tCO2e/year
Scope 2 Emissions:68.67 tCO2e/year
Total Energy Consumption:120.41 MWh/year
Water Consumption:1,481.71 m3/year
Waste Generated:22.83 tons/year
Carbon Intensity:0.98 tons CO2e/employee

ESG Focus Areas

  • Environmental Sustainability
  • Social Responsibility
  • Governance

Environmental Achievements

  • Reduced electricity consumption by 13% compared to 2022

Social Achievements

  • Maintained an “A” from MSCI ESG Rating for two consecutive years
  • Sponsored various events on maternal and perinatal mental health
  • Conducted surveys to understand the needs of CHB and PPD patients

Governance Achievements

  • Maintained an “A” from MSCI ESG Rating for two consecutive years
  • Established a comprehensive ESG governance framework
  • No instances of corruption or bribery reported

Climate Goals & Targets

Long-term Goals:
  • Achieve net-zero emissions (aligned with China's 2060 target)
Short-term Goals:
  • Reduce electricity consumption
  • Improve water efficiency
  • Enhance waste management

Environmental Challenges

  • Low awareness of HBV functional cure among Chinese patients
  • Need to improve access to PPD treatment
  • Managing climate-related risks
Mitigation Strategies
  • Joint survey with iGandan and Beijing You'an Hospital to understand CHB patient needs
  • Research study on PPD patient treatment preferences
  • Implementing energy-saving measures, waste reduction initiatives, and water conservation strategies

Supply Chain Management

Supplier Audits: Routinely audited at least every two years (Tier 1); every three years (Tier 2)

Responsible Procurement
  • Supplier Code of Conduct
  • Comprehensive supplier selection process
  • Supplier qualification assessment

Climate-Related Risks & Opportunities

Physical Risks
  • Extreme weather events
Transition Risks
  • Reputation risks related to climate change
  • Policy changes (carbon pricing)
  • Legal risks (climate-related regulations)
  • Market risks (rising raw material costs)

Reporting Standards

Frameworks Used: HKEX ESG Reporting Guide, SASB Standards, Biopharma investor ESG communications guidance 4.0

Awards & Recognition

  • MSCI ESG Rating 'A'
  • Sina Finance Most Promising Hong Kong Listed Pharmaceutical Companies
  • Gelonghui ESG Pioneer Award